We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hydrogen Sulfide as Prognostic Factor (H2S-1)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01088490
First Posted: March 17, 2010
Last Update Posted: December 5, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Podbregar Matej, University Medical Centre Ljubljana
  Purpose
Hydrogen sulfide (H2S), better known as a poisonous gas, has emerged as the third gaseous transmitter in mammals, next to nitric oxide (NO) and carbon monoxide (CO). Increased production and higher serum concentrations were shown in inflammatory diseases, septic shock and stroke. The investigators will test the hypothesis that higher serum H2S concentrations on admission to intensive care unit (ICU) are linked with higher mortality in patients with shock of any reason.

Condition
Mortality Shock

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Hydrogen Sulfide as Prognostic Factor

Further study details as provided by Podbregar Matej, University Medical Centre Ljubljana:

Primary Outcome Measures:
  • Prognostic value of H2S [ Time Frame: In hospital; ICU mortality 30days ]

    relationship between H2S and mortality of patients during intensive care treatment,

    comparison of H2S and lactate prognostic value



Secondary Outcome Measures:
  • Correlation of H2S with vasopressor requirements [ Time Frame: ICU treatmennt 30days ]
    relationship between H2S and dose of vasopressors (noradrenaline, epinephrine) used


Enrollment: 50
Study Start Date: January 2010
Study Completion Date: January 2014
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
critically ill
Critically ill patients admitted to ICU

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Critically ill patients how are admitted in shock or hemodynamicaly unstable ino intensive care
Criteria

Inclusion Criteria:

  • shock ( systemic arterial pressure less then 120mmHg, elevated lactate > 2.5mmol/L)

Exclusion Criteria:

  • patients admitted due to intoxication with H2S
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01088490


Locations
Slovenia
University Medical Center
Ljubljana, Slovenia, 1000
Sponsors and Collaborators
University Medical Centre Ljubljana
Investigators
Principal Investigator: Matej Podbregar, MD PhD University Medical Centre Ljubljana
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Podbregar Matej, Prof., University Medical Centre Ljubljana
ClinicalTrials.gov Identifier: NCT01088490     History of Changes
Other Study ID Numbers: H2S_1
First Submitted: March 12, 2010
First Posted: March 17, 2010
Last Update Posted: December 5, 2014
Last Verified: December 2014

Keywords provided by Podbregar Matej, University Medical Centre Ljubljana:
Hydrogen sulfide
critically ill
mortality

Additional relevant MeSH terms:
Hydrogen Sulfide
Gasotransmitters
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs